Navigation Links
Human Genome Sciences Announces Process Development and Manufacturing Alliance With Hospira
Date:9/4/2008

d diseases. The Company's primary focus is rapid progress toward the commercialization of its two key lead drugs, Albuferon(R) (albinterferon alfa-2b) for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. Phase 3 clinical trials of both drugs are ongoing.

ABthrax(TM) (raxibacumab) is in late-stage development for the treatment of inhalation anthrax, and the Company is on track to begin the delivery in fall 2008 of 20,000 doses of ABthrax to the Strategic National Stockpile under a contract entered into with the U.S. Government in June 2006. HGS also has three drugs in clinical development for the treatment of cancer, including two TRAIL receptor antibodies and a small-molecule antagonist of IAP (inhibitor of apoptosis) proteins. In addition, HGS has substantial financial rights to certain products in the GSK clinical development pipeline.

For more information about HGS, please visit the Company's web site at http://www.hgsi.com. Health professionals and patients interested in clinical trials of HGS products may inquire via e-mail to clinical_trials@hgsi.com or by calling HGS at (301) 610-5790, extension 3550.

HGS, Human Genome Sciences, ABthrax, Albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company's unproven business model, its dependence on new technologies,
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Conference
2. Ikaria(R) Strengthens Commercial Operations and Human Resources Leadership
3. UC Riverside researcher develops novel method to grow human embryonic stem cells
4. ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
5. DSM Biologics and MorphoSys AG to Manufacture Fully Human Antibody
6. Thousands Rally in Mexico City and Call for Human Rights Protections in Global AIDS Response
7. Human Genome Sciences Announces Second Quarter 2008 Financial Results and Key Developments
8. Human Genome Sciences Appoints David P. Southwell to its Board of Directors
9. Human Genome Sciences to Sponsor Conference Call to Discuss Second Quarter 2008 Financial Results
10. New map IDs the core of the human brain
11. BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 29, 2015  Indivior PLC (LON: INDV) today announced ... spray was accepted and received Priority Review by the ... of opioid overdose. This naloxone nasal spray comes as ... optimal absorption into the nasal mucosa. 1 The ... individuals may be better equipped to help an opioid ...
(Date:7/29/2015)... ... July 29, 2015 , ... CSSi LifeSciences™ ... Valley-based CRO specializing in Clinical Trial Management. CSSi LifeSciences is specialized in strategic, ... expertise of PRC Clinical is focused on Clinical Trial Management, Clinical Site Monitoring, ...
(Date:7/29/2015)... Littleton, MA (PRWEB) , ... July 29, 2015 , ... ... range of serious diseases. Yet few people realize that a rich source of these ... or young adults, and teeth that need to be pulled to make room for ...
(Date:7/28/2015)... 28, 2015 People with a common form ... significant and sometimes profound improvements in their hearing and ... to a new multicenter study led by specialists at ... described online ahead of print in the journal The Laryngoscope ... clinics in the United States ...
Breaking Biology Technology:Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3Advanced Oral and Maxillofacial Surgery (AOMS) in Elmhurst, IL Partners with Provia Labs to make Store-A-Tooth™ Dental Stem Cell Banking Available to their Patients 2Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 2Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 3
... Diego, ... October 4 ... - 7, 2007 -, CHICAGO, Oct. 2 Advanced Life Sciences,Holdings, Inc. ... drugs in the,therapeutic areas of infection, cancer and inflammation, will present four,posters at the Infectious ...
... Pa., Oct. 2 Monitorforhire.com, the,fastest source ... its,service even faster. The company has added ... and respond immediately to work requests via,PDA ... Scott Freedman, president of monitorforhire.com says ...
... Global Advocacy Groups Launch Joint Effort to Preserve Eyesight of,Millions ... reveal that eye exams are being,ignored by many aged over ... in the last year to have their eyes checked, even ... disease or early,death. The survey showed that awareness of glaucoma ...
Cached Biology Technology:Advanced Life Sciences to Present Data from Selected Cethromycin Clinical Trials at the 45th Annual Meeting of the Infectious Diseases Society of America 2Advanced Life Sciences to Present Data from Selected Cethromycin Clinical Trials at the 45th Annual Meeting of the Infectious Diseases Society of America 3International Survey Shows People Over Forty Ignore Risk of Blindness 2International Survey Shows People Over Forty Ignore Risk of Blindness 3International Survey Shows People Over Forty Ignore Risk of Blindness 4International Survey Shows People Over Forty Ignore Risk of Blindness 5
(Date:7/21/2015)... July 21, 2015 Passwords have proven ... in the recent U.S. Office of Personnel Management ... the infosec conundrum, but developers and end-users are ... address this dilemma, Biometrics-as-a-Service provider HYPR Corp. announced ... SDK for third party integration. ...
(Date:7/9/2015)...  Synaptics Inc. (NASDAQ: SYNA ), a leading developer ... report financial results for the fourth quarter and fiscal ... close of market. The company will host a corresponding ... PT (5:00 p.m. ET), during which management may discuss ... live call, analysts and investors should dial 888-455-2260 (conference ...
(Date:7/8/2015)... -- Summary Pancreatic cancer is the 12th most ... a mortality rate of 10.9 deaths per 100,000 people ... has highlighted a significant need for new and improved ... the current market. A highly active pancreatic cancer ... types and mechanisms of action, which provides a striking ...
Breaking Biology News(10 mins):HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... have developed a number of ways to communicate those times ... One means of this communication occurs through scent marking. ... with researchers at the Institute of Zoology, Chinese Academy of ... what trees are used for scent marking. , "Variables ...
... created equal. Some types of fats have been linked to ailments ... in plants and fish, have well documented health benefits. ... but not others? A new hypothesis described in latest ... answer may lie in how different fats interact with the microbes ...
... Ohio - Some RNA molecules spend time in a restful ... established job of delivering protein-building instructions in cells, new research ... mistake, the research suggests that this restful period appears to ... of genes, including some that control cell division and decide ...
Cached Biology News:The Quarterly Review of Biology: Why some fats are worse than others 2To cap or not to cap: Scientists find new RNA phenomenon that challenges dogma 2To cap or not to cap: Scientists find new RNA phenomenon that challenges dogma 3To cap or not to cap: Scientists find new RNA phenomenon that challenges dogma 4
Gridded Cell Culture Petri Dish (20 mm molded in base), tissue-culture treated...
...
...
... PI is used in conjuction with Annexin ... the earlier stages of apoptosis (Annexin V ... in later stages of apoptosis or already ... is detected in the orange range of ...
Biology Products: